Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways

Bibliography

• Ball L. Virus Replication Strategies. In: Edited by Knipe D, Howley P, editor, Fields Virology 5th edition. Philadelphia Wolters Kluwer; 2007. p. 119-39
   Google Scholar
• Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007;15:651-9
   PubMed Web of Science ®Google Scholar
• Liu TC, Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther 2008;15:877-84
   PubMed Web of Science ®Google Scholar
• Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009;227:221-33
   PubMed Web of Science ®Google Scholar
• Seth RB, Sun L, Chen ZJ. Antiviral innate immunity pathways. Cell Res 2006;16:141-7
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006;7:131-7
   PubMed Web of Science ®Google Scholar
• Saito T, Gale M Jr. 1: Principles of intracellular viral recognition. Curr Opin Immunol 2007;19:17-23
   PubMed Web of Science ®Google Scholar
• Bieback K, Lien E, Klagge IM, et al. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol 2002;76:8729-36
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511
   PubMed Web of Science ®Google Scholar
• Uematsu S, Akira S. Toll-like receptors and type I interferons. J Biol Chem 2007;282:15319-23
   PubMed Web of Science ®Google Scholar
• Lund JM, Alexopoulou L, Sato A, et al. Recognition of single-stranded RNA viruses by toll-like receptor 7. Proc Natl Acad Sci USA 2004;101:5598-603
   PubMed Web of Science ®Google Scholar
• Diebold SS, Montoya M, Unger H, et al. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 2003;424:324-8
   PubMed Web of Science ®Google Scholar
• Orvedahl A, Levine B. Autophagy and viral neurovirulence. Cell Microbiol 2008;10:1747-56
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004;5:730-7
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol 2008;20:17-22
   PubMed Web of Science ®Google Scholar
• Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006;441:101-5
   PubMed Web of Science ®Google Scholar
• Takahasi K, Yoneyama M, Nishihori T, et al. Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses. Mol Cell 2008;29:428-40
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Kikuchi M, Matsumoto K, et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 2005;175:2851-8
   PubMed Web of Science ®Google Scholar
• Sato S, Sugiyama M, Yamamoto M, et al. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappaB and IFN-regulatory factor-3, in the toll-like receptor signaling. J Immunol 2003;171:4304-10
   PubMed Web of Science ®Google Scholar
• Takaoka A, Wang Z, Choi MK, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007;448:501-5
   PubMed Web of Science ®Google Scholar
• Wang Z, Choi MK, Ban T, et al. Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci USA 2008;105:5477-82
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008;455:674-8
   PubMed Web of Science ®Google Scholar
• Balachandran S, Roberts PC, Brown LE, et al. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 2000;13:129-41
   PubMed Web of Science ®Google Scholar
• Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008;89:1-47
   PubMed Web of Science ®Google Scholar
• Tenoever BR, Maniatis T. Parallel pathways of virus recognition. Immunity 2006;24:510-2
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann NY Acad Sci 2008;1143:1-20
   PubMed Web of Science ®Google Scholar
• Schindler C, Shuai K, Prezioso VR, Darnell JE Jr. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 1992;257:809-13
   PubMed Web of Science ®Google Scholar
• Hovanessian AG, Justesen J. The human 2'-5'oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2'-5' instead of 3'-5' phosphodiester bond formation. Biochimie 2007;89:779-88
   PubMed Web of Science ®Google Scholar
• Haller O, Stertz S, Kochs G. The Mx GTPase family of interferon-induced antiviral proteins. Microbes Infect 2007;9:1636-43
   PubMed Web of Science ®Google Scholar
• Williams BR. PKR; a sentinel kinase for cellular stress. Oncogene 1999;18:6112-20
   PubMed Web of Science ®Google Scholar
• Balachandran S, Kim CN, Yeh WC, et al. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. Embo J 1998;17:6888-902
   PubMed Web of Science ®Google Scholar
• Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003;424:516-23
   PubMed Web of Science ®Google Scholar
• Chen Q, Gong B, Mahmoud-Ahmed AS, et al. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 2001;98:2183-92
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
   PubMed Web of Science ®Google Scholar
• Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8
   PubMed Web of Science ®Google Scholar
• Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13
   PubMed Web of Science ®Google Scholar
• Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009;9:95-107
   PubMed Web of Science ®Google Scholar
• Battcock SM, Collier TW, Zu D, Hirasawa K. Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway. J Virol 2006;80:4422-30
   PubMed Web of Science ®Google Scholar
• Noser JA, Mael AA, Sakuma R, et al. The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol Ther 2007;15:1531-36
   PubMed Web of Science ®Google Scholar
• Phelps M, Phillips A, Darley M, Blaydes JP. MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm. J Biol Chem 2005;280:16651-8
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009;21:317-37
   PubMed Web of Science ®Google Scholar
• Lin L, Su Z, Lebedeva IV, et al. Activation of Ras/Raf protects cells from melanoma differentiation-associated gene-5-induced apoptosis. Cell Death Differ 2006;13:1982-93
   PubMed Web of Science ®Google Scholar
• Au GG, Lindberg AM, Barry RD, Shafren DR. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int J Oncol 2005;26:1471-6
   PubMed Web of Science ®Google Scholar
• Marozin S, Altomonte J, Stadler F, et al. Inhibition of the IFN-β response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3. Mol Ther 2008;16:1789-97
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25
   PubMed Web of Science ®Google Scholar
• Adamkova L, Souckova K, Kovarik J. Transcription protein STAT1: biology and relation to cancer. Folia Biol (Praha) 2007;53:1-6
   PubMed Web of Science ®Google Scholar
• Ellner PD. Smallpox: gone but not forgotten. Infection 1998;26:263-9
   PubMed Web of Science ®Google Scholar
• Henderson DA, Fenner F. Recent events and observations pertaining to smallpox virus destruction in 2002. Clin Infect Dis 2001;33:1057-9
   PubMed Web of Science ®Google Scholar
• Zhang P, Jacobs BL, Samuel CE. Loss of protein kinase PKR expression in human HeLa cells complements the vaccinia virus E3L deletion mutant phenotype by restoration of viral protein synthesis. J Virol 2008;82:840-8
   PubMed Web of Science ®Google Scholar
• Alcami A, Efstathiou S. Soluble chemokine binding proteins are also encoded by herpesviruses. Immunol Today 2000;21:526-7
   PubMedGoogle Scholar
• Alcami A, Symons JA, Smith GL. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 2000;74:11230-9
   PubMed Web of Science ®Google Scholar
• Haga IR, Bowie AG. Evasion of innate immunity by vaccinia virus. Parasitology 2005;130(Suppl):S11-25
   PubMed Web of Science ®Google Scholar
• Langland JO, Jacobs BL. The role of the PKR-inhibitory genes, E3L and K3L, in determining vaccinia virus host range. Virology 2002;299:133-41
   PubMed Web of Science ®Google Scholar
• Beattie E, Paoletti E, Tartaglia J. Distinct patterns of IFN sensitivity observed in cells infected with vaccinia K3L- and E3L- mutant viruses. Virology 1995;210:254-63
   PubMed Web of Science ®Google Scholar
• Macen JL, Garner RS, Musy PY, et al. Differential inhibition of the Fas- and granule-mediated cytolysis pathways by the orthopoxvirus cytokine response modifier A/SPI-2 and SPI-1 protein. Proc Natl Acad Sci USA 1996;93:9108-13
   PubMed Web of Science ®Google Scholar
• Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009;9:64-71
   PubMed Web of Science ®Google Scholar
• Kirn DH, Wang Y, Le Boeuf F, et al. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 2007;4:e353. published online 27 December 2007, doi:10.1371/journal.pmed.0040353
   PubMed Web of Science ®Google Scholar
• Guo ZS, Naik A, O'Malley ME, et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 2005;65:9991-8
   PubMed Web of Science ®Google Scholar
• Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008;9:533-42
   PubMed Web of Science ®Google Scholar
• Advani SJ, Weichselbaum RR, Whitley RJ, Roizman B. Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications. Clin Microbiol Infect 2002;8:551-63
   PubMed Web of Science ®Google Scholar
• Shen Y, Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 2006;13:975-92
   PubMed Web of Science ®Google Scholar
• Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990;250:1262-6
   PubMed Web of Science ®Google Scholar
• He B, Gross M, Roizman B. The γ134.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1α to dephosphorylate the α subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1997;94:843-8
   PubMed Web of Science ®Google Scholar
• Mundschau LJ, Faller DV. Oncogenic ras induces an inhibitor of double-stranded RNA-dependent eukaryotic initiation factor 2α-kinase activation. J Biol Chem 1992;267:23092-8
   PubMed Web of Science ®Google Scholar
• Mundschau LJ, Faller DV. Endogenous inhibitors of the dsRNA-dependent eIF-2alpha; protein kinase PKR in normal and ras-transformed cells. Biochimie 1994;76:792-800
   PubMed Web of Science ®Google Scholar
• Farassati F, Yang AD, Lee PW. Oncogenes in ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001;3:745-50
   PubMed Web of Science ®Google Scholar
• Farassati F, Pan W, Yamoutpour F, et al. Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am J Pathol 2008;173:1861-72
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Kern ER, Chatterjee S, et al. Replication, establishment of latency, and induced reactivation of herpes simplex virus γ1 34.5 deletion mutants in rodent models. J Clin Invest 1993;91:2837-43
   PubMed Web of Science ®Google Scholar
• Kucharczuk JC, Randazzo B, Chang MY, et al. Use of a “replication-restricted” herpes virus to treat experimental human malignant mesothelioma. Cancer Res 1997;57:466-71
   PubMed Web of Science ®Google Scholar
• McKie EA, MacLean AR, Lewis AD, et al. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours–evaluation of a potentially effective clinical therapy. Br J Cancer 1996;74:745-52
   PubMed Web of Science ®Google Scholar
• Markert JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009;17:199-207
   PubMed Web of Science ®Google Scholar
• Cassady KA. Human cytomegalovirus TRS1 and IRS1 gene products block the double-stranded-RNA-activated host protein shutoff response induced by herpes simplex virus type 1 infection. J Virol 2005;79:8707-15
   PubMed Web of Science ®Google Scholar
• Shah AC, Parker JN, Gillespie GY, et al. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Ther 2007;14:1045-54
   PubMed Web of Science ®Google Scholar
• Schaack J. Induction and inhibition of innate inflammatory responses by adenovirus early region proteins. Viral Immunol 2005;18:79-88
   PubMed Web of Science ®Google Scholar
• Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004;15:1157-66
   PubMed Web of Science ®Google Scholar
• Russell WC. Adenoviruses: update on structure and function. J Gen Virol 2009;90:1-20
   PubMed Web of Science ®Google Scholar
• Frisch SM, Mymryk JS. Adenovirus-5 E1A: paradox and paradigm. Nat Rev Mol Cell Biol 2002;3:441-52
   PubMed Web of Science ®Google Scholar
• Whyte P, Williamson NM, Harlow E. Cellular targets for transformation by the adenovirus E1A proteins. Cell 1989;56:67-75
   PubMed Web of Science ®Google Scholar
• Rao L, Debbas M, Sabbatini P, et al. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci USA 1992;89:7742-6
   PubMed Web of Science ®Google Scholar
• Dix BR, O'Carroll SJ, Myers CJ, et al. Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53. Cancer Res 2000;60:2666-72
   PubMed Web of Science ®Google Scholar
• Lomonosova E, Subramanian T, Chinnadurai G. Mitochondrial localization of p53 during adenovirus infection and regulation of its activity by E1B-19K. Oncogene 2005;24:6796-808
   PubMed Web of Science ®Google Scholar
• White E. Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus. Oncogene 2001;20:7836-46
   PubMed Web of Science ®Google Scholar
• Lichtenstein DL, Toth K, Doronin K, et al. Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol 2004;23:75-111
   PubMed Web of Science ®Google Scholar
• Lichtenstein DL, Doronin K, Toth K, et al. Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2. J Virol 2004;78:12297-307
   PubMed Web of Science ®Google Scholar
• Carmody RJ, Maguschak K, Chen YH. A novel mechanism of nuclear factor-kappaB regulation by adenoviral protein 14.7K. Immunology 2006;117:188-95
   PubMed Web of Science ®Google Scholar
• Wang Y, Hallden G, Hill R, et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 2003;21:1328-35
   PubMed Web of Science ®Google Scholar
• Langland JO, Cameron JM, Heck MC, et al. Inhibition of PKR by RNA and DNA viruses. Virus Res 2006;119:100-10
   PubMed Web of Science ®Google Scholar
• Alemany R. Cancer selective adenoviruses. Mol Aspects Med 2007;28:42-58
   PubMed Web of Science ®Google Scholar
• Aghi M, Martuza RL. Oncolytic viral therapies–the clinical experience. Oncogene 2005;24:7802-16
   PubMed Web of Science ®Google Scholar
• Lu W, Zheng S, Li XF, et al. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol 2004;10:3634-8
   PubMed Web of Science ®Google Scholar
• Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007;7:141-8
   PubMed Web of Science ®Google Scholar
• Liu TC, Wang Y, Hallden G, et al. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. Gene Ther 2005;12:1333-46
   PubMed Web of Science ®Google Scholar
• Liston P, Briedis DJ. Ribosomal frameshifting during translation of measles virus P protein mRNA is capable of directing synthesis of a unique protein. J Virol 1995;69:6742-50
   PubMed Web of Science ®Google Scholar
• Tober C, Seufert M, Schneider H, et al. Expression of measles virus V protein is associated with pathogenicity and control of viral RNA synthesis. J Virol 1998;72:8124-32
   PubMed Web of Science ®Google Scholar
• Cattaneo R, Kaelin K, Baczko K, Billeter MA. Measles virus editing provides an additional cysteine-rich protein. Cell 1989;56:759-64
   PubMed Web of Science ®Google Scholar
• Bellini WJ, Englund G, Rozenblatt S, et al. Measles virus P gene codes for two proteins. J Virol 1985;53:908-19
   PubMed Web of Science ®Google Scholar
• Caignard G, Bourai M, Jacob Y, et al. Inhibition of IFN-alpha/beta signaling by two discrete peptides within measles virus V protein that specifically bind STAT1 and STAT2. Virology 2009;383:112-20
   PubMed Web of Science ®Google Scholar
• Ohno S, Ono N, Takeda M, et al. Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction. J Gen Virol 2004;85:2991-9
   PubMed Web of Science ®Google Scholar
• Fontana JM, Bankamp B, Rota PA. Inhibition of interferon induction and signaling by paramyxoviruses. Immunol Rev 2008;225:46-67
   PubMed Web of Science ®Google Scholar
• Fontana JM, Bankamp B, Bellini WJ, Rota PA. Regulation of interferon signaling by the C and V proteins from attenuated and wild-type strains of measles virus. Virology 2008;374:71-81
   PubMed Web of Science ®Google Scholar
• Peng KW, Ahmann GJ, Pham L, et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001;98:2002-7
   PubMed Web of Science ®Google Scholar
• Phuong LK, Allen C, Peng KW, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003;63:2462-9
   PubMed Web of Science ®Google Scholar
• Grote D, Russell SJ, Cornu TI, et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001;97:3746-54
   PubMed Web of Science ®Google Scholar
• Cattaneo R. Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens' magnet. J Virol 2004;78:4385-8
   PubMed Web of Science ®Google Scholar
• Haralambieva I, Iankov I, Hasegawa K, et al. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol Ther 2007;15:588-97
   PubMed Web of Science ®Google Scholar
• Liu C, Sarkaria JN, Petell CA, et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 2007;13:7155-65
   PubMed Web of Science ®Google Scholar
• Myers RM, Greiner SM, Harvey ME, et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007;82:700-10
   PubMed Web of Science ®Google Scholar
• Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 2009;11:43-53
   PubMed Web of Science ®Google Scholar
• Cassel WA, Garrett RE. Newcastle disease virus as an antineoplastic agent. Cancer 1965;18:863-8
   PubMed Web of Science ®Google Scholar
• Huang Z, Krishnamurthy S, Panda A, Samal SK. Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. J Virol 2003;77:8676-85
   PubMed Web of Science ®Google Scholar
• Park MS, Garcia-Sastre A, Cros JF, et al. Newcastle disease virus V protein is a determinant of host range restriction. J Virol 2003;77:9522-32
   PubMed Web of Science ®Google Scholar
• Hale BG, Randall RE, Ortin J, Jackson D. The multifunctional NS1 protein of influenza A viruses. J Gen Virol 2008;89:2359-76
   PubMed Web of Science ®Google Scholar
• Zamarin D, Martinez-Sobrido L, Kelly K, et al. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther 2009;17:697-706
   PubMed Web of Science ®Google Scholar
• Barber GN. Vesicular stomatitis virus as an oncolytic vector. Viral Immunol 2004;17:516-27
   PubMed Web of Science ®Google Scholar
• Sun X, Yau VK, Briggs BJ, Whittaker GR. Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells. Virology 2005;338:53-60
   PubMed Web of Science ®Google Scholar
• Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003;4:263-75
   PubMed Web of Science ®Google Scholar
• Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000;6:821-5
   PubMed Web of Science ®Google Scholar
• Faria PA, Chakraborty P, Levay A, et al. VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell 2005;17:93-102
   PubMed Web of Science ®Google Scholar
• Lun X, Senger DL, Alain T, et al. Effects of intravenously administered recombinant vesicular stomatitis virus (VSVΔM51) on multifocal and invasive gliomas. J Natl Cancer Inst 2006;98:1546-57
   PubMed Web of Science ®Google Scholar
• Ebert O, Harbaran S, Shinozaki K, Woo SL. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther 2005;12:350-8
   PubMed Web of Science ®Google Scholar
• Hadaschik BA, Zhang K, So AI, et al. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res 2008;68:4506-10
   PubMed Web of Science ®Google Scholar
• Goel A, Carlson SK, Classic KL, et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Δ51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 2007;110:2342-50
   PubMed Web of Science ®Google Scholar
• Obuchi M, Fernandez M, Barber GN. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 2003;77:8843-56
   PubMed Web of Science ®Google Scholar
• Altomonte J, Wu L, Meseck M, et al. Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther 2009;16:266-78
   PubMed Web of Science ®Google Scholar
• Wu L, Huang TG, Meseck M, et al. rVSV(MΔ51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther 2008;19:635-47
   PubMed Web of Science ®Google Scholar
• Altomonte J, Wu L, Chen L, et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther 2008;16:146-53
   PubMed Web of Science ®Google Scholar
• Ebert O, Shinozaki K, Huang TG, et al. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res 2003;63:3605-11
   PubMed Web of Science ®Google Scholar
• Zhang JF, Hu C, Geng Y, et al. Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc Natl Acad Sci USA 1996;93:4513-8
   PubMed Web of Science ®Google Scholar
• Shashkova EV, Spencer JF, Wold WS, Doronin K. Targeting interferon-α increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol Ther 2007;15:598-607
   PubMed Web of Science ®Google Scholar
• Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007;4:101-17
   PubMedGoogle Scholar
• Wein LM, Wu JT, Kirn DH. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 2003;63:1317-24
   PubMed Web of Science ®Google Scholar
• Kelly EJ, Hadac EM, Greiner S, Russell SJ. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med 2008;14:1278-83
   PubMed Web of Science ®Google Scholar
• Kelly EJ, Russell SJ. MicroRNAs and the regulation of vector tropism. Mol Ther 2009;17:409-16
   PubMed Web of Science ®Google Scholar
• Lun XQ, Jang JH, Tang N, et al. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 2009;15:2777-88
   PubMed Web of Science ®Google Scholar
• Nguyen TL, Abdelbary H, Arguello M, et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA 2008;105:14981-6
   PubMed Web of Science ®Google Scholar